Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apelin-13 for SIAD (ESCAPE)
NCT06277336Completed
- Sponsor
- University Hospital Basel
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of apelin-13 in syndrome of inappropriate antidiuresis (SIAD) and hyponatremia (8 arms), sponsored by University Hospital Basel. Primary endpoint: Total urinary excretion. Started Mar 2024; status: completed.
02
Drugs
apelin-13
03
Conditions
syndrome of inappropriate antidiuresis (SIAD)hyponatremia
Beyond the preview
Go deeper on NCT06277336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277336.